The present study focuses on patients with Pseudomonas aeruginosa (PSA) sepsis. The aim of the present study is to find out whether the M1 (pro-inflammatory) or M2 (anti-inflammatory) phenotype predominates in blood monocytes in critically ill patients with PSA-sepsis, and whether the severity of sepsis and outcome is associated with distinct monocyte phenotype and function.
Eligibility
Sex
ALL
Min age
18 Years
Max age
90 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* age \> 18 years
* critically ill patients with sepsis
* microbiologically proven infection with Pseudomonas aeruginosa
Exclusion Criteria:
* life expectancy \< 24 hours
* participation in other studies
Primary outcome measure(s)
Monocyte surface marker expression in critically ill patients with Pseudomonas aeruginosa sepsis — two years Monocyte type 1, type 2 surface marker expression
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.